<p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）预计将在 2025 年第二季度的季度财报发布之前，于 8 月 7 日星期四市场开盘前发布。分析师预计该公司将宣布每股收益为（$0.02），季度收入为 4760 万美元。</p>
<ul>
<li>Akebia Therapeutics 因 FDA 批准贫血治疗而大幅上涨</li>
</ul>
<p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）最近一次发布季度财报是在 5 月 8 日星期四。这家生物制药公司报告该季度每股收益为$0.03，超出分析师一致预期的（$0.03）$0.06。该公司在该季度的收入为 5734 万美元，而分析师预期为 4488 万美元。分析师平均预计 Akebia Therapeutics 在当前财政年度的每股收益为$0，下一财政年度的每股收益也为$0。</p>
<p>获取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
<h2>Akebia Therapeutics 股价上涨 0.8%</h2>
<p>在周五的午盘交易中，纳斯达克 AKBA 的股票上涨了$0.03，达到了$3.72。该股票的交易量为 3,017,137 股，而其平均交易量为 4,131,279 股。该公司的市值为 9.7702 亿美元，市盈率为-17.71，贝塔值为 0.88。Akebia Therapeutics 的 12 个月低点为$1.07，12 个月高点为$4.08。该公司的债务与股本比率为 1.89，速动比率为 2.02，流动比率为 2.23。该公司的 50 日移动平均价格为$3.61，200 日移动平均价格为$2.64。</p>
<h2>Akebia Therapeutics 的内部交易</h2>
<p>在相关消息中，首席财务官 Erik Ostrowski 于 6 月 30 日星期一出售了 41,314 股公司的股票，交易价格为每股平均$3.67，总价值为$151,622.38。交易后，首席财务官持有 503,586 股公司股票，价值约为$1,848,160.62。此次交易代表其持股比例下降了 7.58%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席会计官 Richard C. Malabre 于 6 月 9 日星期一出售了 15,000 股公司的股票，交易价格为每股平均$4.01，总交易额为$60,150.00。交易完成后，首席会计官直接持有 266,914 股公司股票，价值约为$1,070,325.14。此次交易代表其持股比例下降了 5.32%。该出售的披露信息可在此找到。在过去三个月中，内部人士共出售了 69,648 股公司股票，价值$258,841。内部人士持有公司股票的比例为 3.00%。</p>
<h2>对 Akebia Therapeutics 的对冲基金看法</h2>
<p>几家大型投资者最近增加或减少了对该公司的持股。高盛集团在第一季度将其在 Akebia Therapeutics 的持股比例提高了 171.8%。高盛集团目前拥有 2,724,439 股生物制药公司的股票，价值$5,231,000，此前在上个季度又购买了 1,722,245 股。AQR 资本管理公司在第一季度将其在 Akebia Therapeutics 的持股比例提高了 13.1%。AQR 资本管理公司目前拥有 176,961 股生物制药公司的股票，价值$340,000，此前在上个季度又购买了 20,499 股。未来资产全球 ETF 控股有限公司在第一季度将其在 Akebia Therapeutics 的持股比例提高了 9.1%。未来资产全球 ETF 控股有限公司目前拥有 137,897 股生物制药公司的股票，价值$265,000，此前在上个季度又购买了 11,517 股。最后，贝尔德金融集团在第一季度将其在 Akebia Therapeutics 的持股比例提高了 23.0%。贝尔德金融集团目前拥有 21,393 股生物制药公司的股票，价值$41,000，此前在上个季度又购买了 4,000 股。机构投资者持有公司股票的比例为 33.92%。</p>
<h2>华尔街分析师的看法</h2>
<p>一些分析师对 AKBA 股票发表了看法。Leerink Partners 在 4 月 28 日星期一的报告中将 Akebia Therapeutics 的评级上调至 “强力买入”。HC Wainwright 在 6 月 4 日星期三的报告中开始覆盖 Akebia Therapeutics。他们为该公司设定了 “买入” 评级和$8.00 的目标价。Wall Street Zen 在 5 月 3 日星期六的报告中将 Akebia Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Leerink Partners 在 4 月 28 日星期一的报告中对 Akebia Therapeutics 进行了覆盖。他们为该公司设定了 “跑赢大盘” 的评级和$7.00 的目标价。一位股票研究分析师对该股票给予了持有评级，四位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat.com 的数据，Akebia Therapeutics 目前的平均评级为 “买入”，平均目标价为$6.75。</p>
<p><strong>查看我们关于 AKBA 的最新报告</strong></p>
<h2>关于 Akebia Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Akebia Therapeutics, Inc.是一家生物制药公司，专注于开发和商业化针对肾脏疾病患者的治疗药物。该公司的主要产品候选药物是 Vafseo（vadadustat），这是一种口服缺氧诱导因子脯氨酸羟化酶抑制剂，目前正在进行 III 期临床试验，旨在治疗因慢性肾病（CKD）导致的贫血，适用于依赖透析和不依赖透析的患者。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 Akebia Therapeutics 更好</li>
<li>投资的股票类型有不同</li>
<li>保持冷静：为什么 Comfort Systems USA 是一个隐藏的 AI 赢家</li>
<li>什么是财报？</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>股息支付比率计算器</li>
<li>苹果股票：大额收益，小幅波动——是时候买入了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Akebia Therapeutics 吗？</h2>
<p>在考虑 Akebia Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Akebia Therapeutics 并不在名单上。</p>
<p>虽然 Akebia Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AKBA

<p>Akebia Therapeutics（纳斯达克代码：AKBA）将于 8 月 7 日发布 2025 年第二季度财报，分析师预测每股收益为（$0.02），收入为 4760 万美元。该公司最近报告了 2025 年第一季度每股收益为$0.03，超出预期。股价上涨 0.8%，至$3.72，市值为 9.7702 亿美元。内部交易活动包括首席财务官 Erik Ostrowski 出售股份，机构投资者持有 33.92% 的股份。分析师对该股的评级不一，有些将其评级上调至 “强力买入”，并设定目标价高达$8.00</p>

<p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $47.60 million for the quarter.</p>
<div class="lb-trans"><p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）预计将在 2025 年第二季度的季度财报发布之前，于 8 月 7 日星期四市场开盘前发布。分析师预计该公司将宣布每股收益为（$0.02），季度收入为 4760 万美元。</p>
</div><ul>
<li>Akebia Therapeutics Surges on FDA Approval for Anemia Treatment</li>
</ul>
<div class="lb-trans"><ul>
<li>Akebia Therapeutics 因 FDA 批准贫血治疗而大幅上涨</li>
</ul>
</div><p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.06. The firm had revenue of $57.34 million during the quarter, compared to analyst estimates of $44.88 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）最近一次发布季度财报是在 5 月 8 日星期四。这家生物制药公司报告该季度每股收益为$0.03，超出分析师一致预期的（$0.03）$0.06。该公司在该季度的收入为 5734 万美元，而分析师预期为 4488 万美元。分析师平均预计 Akebia Therapeutics 在当前财政年度的每股收益为$0，下一财政年度的每股收益也为$0。</p>
</div><p>Get <strong>Akebia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
</div><h2>Akebia Therapeutics Trading Up 0.8%</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 股价上涨 0.8%</h2>
</div><p>Shares of NASDAQ AKBA traded up $0.03 during midday trading on Friday, reaching $3.72. The stock had a trading volume of 3,017,137 shares, compared to its average volume of 4,131,279. The firm has a market cap of $977.02 million, a price-to-earnings ratio of -17.71 and a beta of 0.88. Akebia Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.08. The company has a debt-to-equity ratio of 1.89, a quick ratio of 2.02 and a current ratio of 2.23. The company's 50 day moving average price is $3.61 and its 200 day moving average price is $2.64.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克 AKBA 的股票上涨了$0.03，达到了$3.72。该股票的交易量为 3,017,137 股，而其平均交易量为 4,131,279 股。该公司的市值为 9.7702 亿美元，市盈率为-17.71，贝塔值为 0.88。Akebia Therapeutics 的 12 个月低点为$1.07，12 个月高点为$4.08。该公司的债务与股本比率为 1.89，速动比率为 2.02，流动比率为 2.23。该公司的 50 日移动平均价格为$3.61，200 日移动平均价格为$2.64。</p>
</div><h2>Insider Transactions at Akebia Therapeutics</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 的内部交易</h2>
</div><p>In related news, CFO Erik Ostrowski sold 41,314 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $3.67, for a total value of $151,622.38. Following the transaction, the chief financial officer owned 503,586 shares of the company's stock, valued at approximately $1,848,160.62. This trade represents a 7.58% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CAO Richard C. Malabre sold 15,000 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $4.01, for a total transaction of $60,150.00. Following the completion of the transaction, the chief accounting officer directly owned 266,914 shares in the company, valued at approximately $1,070,325.14. The trade was a 5.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,648 shares of company stock worth $258,841 in the last three months. Insiders own 3.00% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Erik Ostrowski 于 6 月 30 日星期一出售了 41,314 股公司的股票，交易价格为每股平均$3.67，总价值为$151,622.38。交易后，首席财务官持有 503,586 股公司股票，价值约为$1,848,160.62。此次交易代表其持股比例下降了 7.58%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席会计官 Richard C. Malabre 于 6 月 9 日星期一出售了 15,000 股公司的股票，交易价格为每股平均$4.01，总交易额为$60,150.00。交易完成后，首席会计官直接持有 266,914 股公司股票，价值约为$1,070,325.14。此次交易代表其持股比例下降了 5.32%。该出售的披露信息可在此找到。在过去三个月中，内部人士共出售了 69,648 股公司股票，价值$258,841。内部人士持有公司股票的比例为 3.00%。</p>
</div><h2>Hedge Funds Weigh In On Akebia Therapeutics</h2>
<div class="lb-trans"><h2>对 Akebia Therapeutics 的对冲基金看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its position in shares of Akebia Therapeutics by 171.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company's stock worth $5,231,000 after buying an additional 1,722,245 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Akebia Therapeutics by 13.1% during the 1st quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company's stock worth $340,000 after buying an additional 20,499 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Akebia Therapeutics by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company's stock worth $265,000 after buying an additional 11,517 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in shares of Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 33.92% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对该公司的持股。高盛集团在第一季度将其在 Akebia Therapeutics 的持股比例提高了 171.8%。高盛集团目前拥有 2,724,439 股生物制药公司的股票，价值$5,231,000，此前在上个季度又购买了 1,722,245 股。AQR 资本管理公司在第一季度将其在 Akebia Therapeutics 的持股比例提高了 13.1%。AQR 资本管理公司目前拥有 176,961 股生物制药公司的股票，价值$340,000，此前在上个季度又购买了 20,499 股。未来资产全球 ETF 控股有限公司在第一季度将其在 Akebia Therapeutics 的持股比例提高了 9.1%。未来资产全球 ETF 控股有限公司目前拥有 137,897 股生物制药公司的股票，价值$265,000，此前在上个季度又购买了 11,517 股。最后，贝尔德金融集团在第一季度将其在 Akebia Therapeutics 的持股比例提高了 23.0%。贝尔德金融集团目前拥有 21,393 股生物制药公司的股票，价值$41,000，此前在上个季度又购买了 4,000 股。机构投资者持有公司股票的比例为 33.92%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of analysts have weighed in on AKBA shares. Leerink Partnrs upgraded Akebia Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, April 28th. HC Wainwright started coverage on Akebia Therapeutics in a report on Wednesday, June 4th. They set a &#34;buy&#34; rating and a $8.00 price target for the company. Wall Street Zen upgraded Akebia Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, May 3rd. Finally, Leerink Partners initiated coverage on Akebia Therapeutics in a report on Monday, April 28th. They set an &#34;outperform&#34; rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Akebia Therapeutics presently has an average rating of &#34;Buy&#34; and an average price target of $6.75.</p>
<div class="lb-trans"><p>一些分析师对 AKBA 股票发表了看法。Leerink Partners 在 4 月 28 日星期一的报告中将 Akebia Therapeutics 的评级上调至 “强力买入”。HC Wainwright 在 6 月 4 日星期三的报告中开始覆盖 Akebia Therapeutics。他们为该公司设定了 “买入” 评级和$8.00 的目标价。Wall Street Zen 在 5 月 3 日星期六的报告中将 Akebia Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Leerink Partners 在 4 月 28 日星期一的报告中对 Akebia Therapeutics 进行了覆盖。他们为该公司设定了 “跑赢大盘” 的评级和$7.00 的目标价。一位股票研究分析师对该股票给予了持有评级，四位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat.com 的数据，Akebia Therapeutics 目前的平均评级为 “买入”，平均目标价为$6.75。</p>
</div><p><strong>Check Out Our Latest Report on AKBA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 AKBA 的最新报告</strong></p>
</div><h2>About Akebia Therapeutics</h2>
<div class="lb-trans"><h2>关于 Akebia Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.</p>
<div class="lb-trans"><p>Akebia Therapeutics, Inc.是一家生物制药公司，专注于开发和商业化针对肾脏疾病患者的治疗药物。该公司的主要产品候选药物是 Vafseo（vadadustat），这是一种口服缺氧诱导因子脯氨酸羟化酶抑制剂，目前正在进行 III 期临床试验，旨在治疗因慢性肾病（CKD）导致的贫血，适用于依赖透析和不依赖透析的患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Akebia Therapeutics</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Play It Cool: Why Comfort Systems USA Is a Hidden AI Winner</li>
<li>What Are Earnings Reports?</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Akebia Therapeutics 更好</li>
<li>投资的股票类型有不同</li>
<li>保持冷静：为什么 Comfort Systems USA 是一个隐藏的 AI 赢家</li>
<li>什么是财报？</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>股息支付比率计算器</li>
<li>苹果股票：大额收益，小幅波动——是时候买入了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AKBA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Akebia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Akebia Therapeutics 吗？</h2>
</div><p>Before you consider Akebia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Akebia Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Akebia Therapeutics 并不在名单上。</p>
</div><p>While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Akebia Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Akebia Therapeutics (AKBA) 将在周四公布财报